Related Experiment Video
Updated: Jun 2, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Multiple effects of angiopoietin-2 blockade on tumors
Claire E Lewis1, Napoleone Ferrara
1Academic Unit of Inflammation and Tumour Targeting, The University of Sheffield Medical School, Sheffield, UK. claire.lewis@sheffield.ac.uk
Cancer Cell
|April 13, 2011
Abstract:
In this issue of Cancer Cell, Mazzieri, Pucci, and colleagues describe the marked effects of inhibiting the proangiogenic cytokine, Angiopoietin-2, on tumor angiogenesis and progression in spontaneous tumor models, as well as the proangiogenic functions of TIE2-expressing macrophages.
Insights
Inhibiting Angiopoietin-2 significantly impacts tumor growth and blood vessel formation in models. This study also reveals the role of TIE2-expressing macrophages in promoting tumor angiogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Tumor angiogenesis is crucial for cancer progression.
- Angiopoietin-2 (Ang-2) is a key proangiogenic factor implicated in various cancers.
- TIE2-expressing macrophages (TEMs) are increasingly recognized for their role in the tumor microenvironment.
Discussion:
- Mazzieri, Pucci, and colleagues investigated the therapeutic potential of inhibiting Ang-2.
- The study utilized spontaneous tumor models to assess the effects of Ang-2 inhibition.
- The proangiogenic functions of TEMs were also explored in relation to Ang-2 signaling.
Key Insights:
- Inhibition of Ang-2 demonstrated marked effects on tumor angiogenesis and progression.
- Targeting Ang-2 offers a potential strategy for cancer therapy.
- TEMs contribute to tumor angiogenesis, highlighting them as potential therapeutic targets.
Outlook:
- Further research is warranted to explore combination therapies involving Ang-2 inhibitors and immunomodulatory agents.
- Clinical trials are needed to validate the efficacy of Ang-2 inhibition in human cancers.
- Understanding the intricate crosstalk between Ang-2, TEMs, and tumor growth could lead to novel therapeutic approaches.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...